13F Holdings
中文EN

BNR Burning Rock Biotech Ltd Annual reports only

Services-Medical Laboratories · Nasdaq · SEC CIK 1792267

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-4.0%
TTM net income YoY47.0%
TTM EPS YoY—
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—

Margins

Gross margin70.3%
Operating margin-69.3%
Net margin-67.2%
FCF margin-18.9%
EBITDA margin-59.2%

Returns

ROE-51.4%
ROA-36.0%
ROIC (approx.)-263.6%
Asset turnover0.54x

Leverage & solvency

Liabilities / assets34.4%
Debt / equity0.00x
Current ratio2.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.27x
Accruals ratio-26.4%
Payout ratio—
Capex / revenue1.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31 · USDFY20242024-12-31 · CNYFY20232023-12-31 · CNYFY20222022-12-31 · USDFY20212021-12-31 · CNY
Income statement
Revenue$77.16M515.82M537.43M$81.66M507.86M
Cost of revenue$19.54M153.42M174.21M$26.56M143.72M
Gross profit$57.62M362.40M363.23M$55.10M364.15M
R&D expense$23.81M232.29M347.02M$61.16M367.86M
SG&A expense$18.03M261.64M437.82M$82.39M490.26M
Operating income-$7.84M-357.56M-669.32M-$142.15M-797.06M
Interest expense————1.54M
Pretax income-$7.69M-340.74M-651.30M-$140.53M-795.80M
Income tax$223,0005.88M2.39M$288,000899,000
Net income-$7.92M-346.63M-653.69M-$140.81M-796.70M
EBITDA-$4.73M-305.36M-535.92M-$124.15M-749.30M
EPS (basic)————0.00
EPS (diluted)————0.00
Weighted avg. shares (diluted)————0
Banking
Net interest income-$4,00000$15,000-1.54M
Balance sheet
Cash & equivalents$68.41M519.85M615.10M$130.32M1.44B
Short-term investments———$063.76M
Receivables$24.25M152.01M126.86M$15.94M92.20M
Inventory$6.95M53.76M69.02M$18.89M123.21M
Current assets$105.62M776.62M884.10M$182.50M1.82B
PP&E, net$4.45M47.15M131.91M$36.51M325.44M
Intangibles$41,000421,000964,000$288,0005.15M
Total assets$117.31M885.30M1.04B$230.16M2.28B
Current liabilities$35.32M266.30M263.36M$59.66M372.18M
Short-term debt———$02.37M
Long-term debt$243,0000———
Total debt$243,0000———
Total liabilities$40.77M304.48M271.59M$62.22M433.28M
Shareholders' equity$76.54M580.83M768.41M$167.94M1.85B
Net debt-$68.17M-519.85M———
Cash flow statement
Operating cash flow-$4.07M-92.26M-255.78M-$66.23M-477.89M
Capital expenditure$751,0005.42M8.10M$8.99M204.33M
Free cash flow-$4.82M-97.68M-263.89M-$75.23M-682.22M
Investing cash flow-$628,000-4.41M-9.30M-$1.08M81.70M
Financing cash flow$272,000-72,000-48.83M-$12.50M-52.90M
Depreciation & amortization$3.11M52.20M133.40M$17.99M47.77M
Stock-based compensation$1.98M155.62M260.72M$47.38M282.43M
Share buybacks————0

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.